

Polar Capital Future Healthcare

a sub-fund of Premium Selection UCITS ICAV

Class Ah - dis - EUR, ISIN IE00BNGJL970

March 2024 Factsheet

This document is marketing material. Unless otherwise stated all data as at 31/03/2024.

Investors should read the Key Investor Information Document and Prospectus prior to investing.



FUND OVERVIEW


The Fund aims to preserve capital and achieve long term capital appreciation, by investing in a globally diversified portfolio of companies within the healthcare sector. The Fund invests directly or indirectly up to 100% of its Net Asset Value (and typically at least two thirds of its Net Asset Value) in equities and equity related securities of healthcare companies worldwide, which may be listed on a Regulated Market or unlisted. The Fund may invest up to 10% of its Net Asset Value in global listed securities other than healthcare related companies and up to 30% of its Net Asset Value in ancillary liquid assets and cash. The total amount of these investments is limited to a third of the Fund's Net Asset Value. Up to 30% of the Net Asset Value may be invested in emerging markets. The Fund may invest up to 20% of its Net Asset Value in equity warrants, up to 20% of its Net Asset Value in Depositary Receipts (including ADRs, EDRs and/or GDRs) and up to 10% of its Net Asset Value in participatory notes. The Fund can invest directly or indirectly up to 20% of its Net Asset Value in China A shares via both, the Shanghai-Hong Kong Stock Connect or the Shenzhen-Hong Kong Stock Connect and China H-shares traded on the Hong Kong Stock Exchange. The Fund may use financial derivatives for efficient portfolio management and/or hedging purposes. The Fund may use investment techniques known as 'hedging' to provide protection against exchange risks for the efficient management of its investments or to hedge a non-base currency share class. Such techniques may include options, forwards, futures, swaps and securities lending agreements. The Fund may be leveraged up to 100% of the Fund's NAV. The Fund may invest up to 10% of its Net Asset Value in other collective investment schemes.

FUND OPPORTUNITIES

A highly qualified and experienced investment manager actively manages the Fund. Equities are selected using a stock selection process to generate a high conviction portfolio participating in specific themes, which are identified as the future of healthcare, namely, future medicines and technologies, new markets, healthcare delivery, prevention and outsourcing.

RISK FACTORS

A significant portion of the Fund's assets may be invested in emerging market assets. Emerging markets generally carry greater political, legal, counterparty and operational risk. In exceptional circumstances the Fund may encounter difficulties when buying and selling these investments. Due to the fact that the Fund may invest into the China A Shares market via both, Shanghai-Hong Kong Stock Connect and/or Shenzhen-Hong Kong Stock Connect, various additional risks which include but are not limited to regulatory risks and suspension risks may thereby be caused and should be emphasised to the general investment and equity related risks.



Source: Three Rock Capital Management Ltd., MSCI. The Fund was established in April 2021. This Class was created in April 2021. Share Class and Benchmark performance displayed in EUR. Performance is shown on a Net Asset Value (NAV) basis, with gross income reinvested.

Past performance is not necessarily indicative of future performance and should not be the sole factor of consideration when selecting a product.

All financial investments involve an element of risk. Therefore, the value of your investment and the income from it will vary and your initial investment amount cannot be guaranteed

RISK AND REWARD PROFILE

Lower Risk				Higher Risk		
Typically Lower Rewards				Typically Higher Rewards		
1	2	3	4	5	6	7

KEY FACTS

ISIN	IE00BNGJL970
Valoren	59202676
Management Company	Three Rock Capital Management Ltd.
Investment Manager	Polar Capital LLP
Asset Class	Equity
Share Class Currency	EUR
Base Currency	USD
Benchmark	MSCI AC World Daily Total Return Net Health Care USD Index
Fund Inception Date	09/04/2021
Share Class Launch Date	09/04/2021
Domicile	Ireland
Fund Type	UCITS
Minimum Initial Investment	EUR 1,000
Settlement	Trade Date + 2 BD
Dealing Frequency	Daily
Distribution	Annually
Total Fund Assets	USD 141.62 m
Total Share Class Assets	EUR 0.81 m

FEES AND CHARGES

Ongoing charges	1.55%
Entry charge	Max 5.00%
Exit charge	Max 3.00%
TER	1.55%
Performance fees	0.00%


TOP 10 HOLDINGS (%)

ELI LILLY & CO	8.15
ZEALAND PHARMA A/S	8.00
SWEDISH ORPHAN BIOVITRUM AB	7.20
INTUITIVE SURGICAL INC	5.39
JOHNSON & JOHNSON	5.34
HCA HEALTHCARE INC	5.20
MAX HEALTHCARE INSTITUTE LTD	4.80
ACADIA HEALTHCARE CO INC	3.84
CHEMED CORP	3.72
XENON PHARMACEUTICALS INC	3.69
Total of Portfolio	55.33


CURRENCY EXPOSURE (%)

UNITED STATES DOLLAR	56.53
DANISH KRONE	8.02
SWEDISH KRONA	7.21
JAPANESE YEN	6.70
EURO	6.36
INDIAN RUPEE	4.81
HONG KONG DOLLAR	3.17
UNITED KINGDOM POUND STERLING	3.05
HUNGARIAN FORINT	2.49
SWISS FRANC	1.66
Total of Portfolio	100.00

SECTOR EXPOSURE



COUNTRY EXPOSURE



Source: Three Rock Capital Management Ltd. All data shown is subject to change.

GLOSSARY

Business Day (BD): any bank working day in Ireland.

Benchmark (BM): an index that can be used by an investment fund as the basis of comparison for assessing the performance achieved.

Ongoing Charges: is a figure representing all annual charges and other payments taken from the fund.

SRRI: is value based on the volatility of the fund, which gives an indication of the overall risk and reward profile of the Fund.

IMPORTANT LEGAL INFORMATION

Source: Three Rock Capital Management Ltd. (TRCM), unless otherwise stated. Where applicable and, unless otherwise noted, performance is shown net of fees, on a NAV to NAV basis, gross of taxes. TRCM has not independently verified the information from other sources and TRCM gives no assurance, expressed or implied, as to whether such information is accurate, true or complete. All data and information provided is updated at the date of this Document, unless otherwise indicated. All financial investments involve an element of risk. Therefore, the value of your investment and the income from it will vary and your initial investment amount cannot be guaranteed. Premium Selection UCITS ICAV (PSI) is an open-ended investment company established in Ireland which is available for sale in certain jurisdictions only. PSI is not available for sale in the U.S. or to U.S. persons. Product information concerning PSI may not be published in the U.S. Subscriptions in any sub-fund of the PSI are valid only if made on the basis of the current Prospectus and respective Supplement, the most recent financial reports and the Key Investor Information Document (KIID), which are available on www.fundinfo.com. Prospectuses, Key Investor Information Documents and application forms may not be available to investors in certain jurisdictions where the Fund in question has not been authorised. This material is produced by PSI with the greatest of care and to the best of its knowledge and belief. Data and information may not be reproduced or redistributed without permission of PSI. PSI provides no guarantee with regard to the content and completeness of this material and does not accept any liability for losses which might arise from making use of this information. This document is not intended for distribution to or use by persons or entities with nationality of or with their residence, domicile or registered office in a State or Country in which such distribution, publication, making available or use is contrary to laws or other regulations. Nothing contained herein constitutes investment, legal, tax or other advice, nor is it to be solely relied on in making an investment or other decision. This document qualifies as marketing material. The views expressed herein are those of the manager at the time and are subject to change. The price of shares may go down as well as up and the price will depend on fluctuations in financial markets outside our control. As a result an investor may not get back the amount invested. Past performance is not indicative of future performance and reference to a security is not a recommendation to buy or sell that security. Allocations and holdings are subject to change. This is not an invitation to invest in any TRCM product or strategy. This material mentions one or several sub-funds of Premium Selection UCITS ICAV, registered office at 1 WML, Windmill Lane, Dublin 2, Ireland, an umbrella with variable capital and segregated liability between the sub-funds, incorporated under the laws of Ireland and authorised by the Central Bank of Ireland (CBI) as a UCITS Fund in accordance with the Directive 2009/65/EC. Management Company is Three Rock Capital Management Limited, a wholly owned subsidiary of Julius Baer Group AG, with registered office at 61 Thomas Street Dublin 8, Ireland. A summary of investor rights and details for local language investor redress arrangements can be found at www.threerockcapital.com/cbdr.

Source: MSCI. Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.

SWITZERLAND: 1741 Fund Solutions AG, Burggraben 16, CH-9000 St. Gallen, is the Swiss Representative and Telco AG, Bahnhofstrasse 4, Postfach 713, CH-6431 Schwyz, the Swiss Paying Agent. The Prospectus, Key Investor Information Document, the Instrument of Incorporation, the latest and any previous annual and semi-annual reports, in German as applicable, are available free of charge from the Swiss representative. GERMANY: The legal documents in English and the KIID in German can be obtained free of charge, from the Information Agent GerFIS – German Fund Information Service UG (Haftungsbeschränkt) Zum Eichhagen 4, 21382 Brietlingen, Germany or on the internet at www.fundinfo.com. AUSTRIA: The legal documents in English and the KIID in German can be obtained free of charge, from the Paying and Information Agent in Austria, Erste Bank der oesterreichischen Sparkassen AG, Am

Belvedere 1, 1100 Vienna, Austria or on the internet at www.fundinfo.com. FRANCE: The prospectus, the annual report and the most recent half-yearly report in English and the KIID in French can be obtained free of charge from the centralising agent in France Société Générale, 29, Boulevard Haussmann 75009 Paris OR on the internet at www.fundinfo.com. The prospectus is not available in French. LUXEMBOURG: The legal documents in English can be obtained free of charge, from the Local Representative in Luxembourg Société Générale Luxembourg (centre opérationnel), 28-32 Place de la gare, L - 1616 Luxembourg or on the internet at www.fundinfo.com. NETHERLANDS: The English version of the prospectus and the English version of the KIID can be obtained free of charge on the internet at www.fundinfo.com. Before investing, read the Prospectus and respective Supplement and the KIID. SINGAPORE: In Singapore, this material is limited to institutional and accredited investors (as defined in the Securities and Futures Act (Cap.289)) ("SFA") only and does not constitute to an offer to subscribe for shares in any of the funds mentioned herein. A copy of the prospectus or profile statement is available and can be obtained at www.fundinfo.com. This advertisement or publication has not been reviewed by the Monetary Authority of Singapore. For distributing share classes, dividends are not guaranteed and may be paid out of capital. Dividend data may not be available on the issue date of this factsheet. Details on distribution may be available on request. Payments on dividends result in a reduction of the NAV per share of the Fund on the ex-dividend date. Actual dividend payout will be subject to the manager's discretion. Fund performance is shown on a NAV to NAV basis on the assumption that all distributions are reinvested, taking into account all charges which would have been payable upon such reinvestment. SPAIN: The legal documents in English and the KIID in Spanish can be obtained free of charge from the representative in Spain, Allfunds Bank S.A.U, C/ Padres Dominicos 7, 28050 Madrid, Spain or on the internet at www.fundinfo.com. The Fund is registered with the CNMV under 1964. UK: As far as UCITS domiciled in Ireland described herein are recognised schemes under section 264 of the Financial Services and Markets Act 2000: Copies of the legal documents can be obtained in English, free of charge, from the Facilities Agent Carne Financial Services (UK) LLP and address is 2nd Floor, 107 Cheapside, London, EC2V 6ND, United Kingdom or on the internet at www.fundinfo.com. Investments in the funds are not protected by the Financial Services Compensation Scheme. ITALY: The Fund(s) mentioned in this document is/are notified for marketing in Italy to professional and retail investors. Past performance is not indicative of future performance. Before investing, read the Prospectus and respective Supplement (in English) and the KIID (in Italian) available on www.fundinfo.com. DENMARK: The PSI has appointed StockRate Asset Management A/S, Sdr. Jernbanevej 18D, 3400 Hillerød, Denmark, as its Danish representative. For further information, please be referred to the Prospectus and relevant Country Supplement of the fund. HONG KONG: This factsheet has not been reviewed or approved by the Securities and Futures Commission in Hong Kong or the Companies Registry of Hong Kong and, accordingly, the Shares may not be offered or sold in Hong Kong by means of this factsheet or any other document other than to persons outside Hong Kong, or to "professional investors" (as this term is defined in the SFO and the subsidiary legislation made thereunder), or in circumstances that do not result in this factsheet being a "prospectus" as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the laws of Hong Kong) ("CO (Cap. 32)"), or in circumstances that do not constitute an offer or an invitation to the public for the purposes of the HK SFO or the CO (Cap. 32). Offers of Shares will not be and may not be made to any person in Hong Kong other than a person to whom this factsheet has been issued by or on behalf of the Manager, as applicable. No person to whom this factsheet is given by or on behalf of the Manager may issue, circulate or distribute this factsheet in Hong Kong or make or give a copy of this factsheet to any person. Dubai International Financial Centre (DIFC): If this information relates to the offering of units in a Fund (as defined in the Collective Investment Law DIFC Law No. 2 of 2010), please note that any such Fund is not subject to any form of regulation or approval by the Dubai Financial Services Authority (DFSA). The DFSA has no responsibility for reviewing or verifying any Prospectus (as defined in the Collective Investment Law DIFC Law No. 2 of 2010) or other associated documents in connection with this Fund. Accordingly, the DFSA has not approved any Prospectus or any other associated documents, nor taken any steps to verify the information set out in therein, and has no responsibility for it. The Units (as defined in the Collective Investment Law DIFC Law No. 2 of 2010) to which this Prospectus or other associated documents relate, may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the units offered should conduct their own due diligence on the units. Past performance of a Fund is no guarantee of current or future performance. If you do not understand the contents of the Prospectus or other associated documents, you should consult an authorised financial adviser and/or seek independent and specialist legal advice. A copy of the Fund Prospectus is available for review upon request. PORTUGAL: The legal documents in English and the KIID in Portuguese can be obtained free of charge from the Paying Agent, BancoBest at Praça Marquês de Pombal, 3A, 3, Lisbon, Portugal and on the internet at www.fundinfo.com.